

### REMARKS

The amendment to the priority claim is being made in the above-identified application to correct an inadvertent error in the priority claim in the application as originally filed. The above-identified application is entitled to claim benefit of the filing date of the U.S. application Serial No. 08/449,649 under 35 U.S.C. §120. Therefore please enter the above amendment which corrects the priority claim.


Amendment to the specification is made to bring the disclosure of particular nucleic acid and amino acid sequences, and the Sequence Listing itself in line with 37 C.F.R. §1.821(c). A computer readable form of the Sequence Listing in accordance with 37 C.F.R. §1.821(e) is concurrently submitted herewith. The content of the paper copy and computer readable forms are the same as required under 37 C.F.R. §1.821(f).

The addition of the Sequence Listing necessitates renumbering subsequent pages in the application. Renumbering of the pages in the claims and abstract is requested to maintain clarity in the order of the application and adds no new matter to the application.

If the Examiner believes that submission of a substitute specification incorporating the above-requested amendments would materially facilitate handling by the Patent Office, telephone advice of the same to the undersigned would be appreciated.

Respectfully submitted,  
MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

By

  
David W. Clough  
(Reg. No. 36,107)  
Attorneys for Applicant(s)  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

Chicago, Illinois  
June 26, 2000